A prognostic gene signature based on focal adhesion related genes for gliomas and identification of the role of RAP1B in glioma progression DOI Creative Commons
Ning Wang, Haoyu Zhou, Tianze Wang

et al.

Research Square (Research Square), Journal Year: 2023, Volume and Issue: unknown

Published: Oct. 18, 2023

Abstract Background The most common malignant primary brain tumor in adults is the gliomas, characterized by extremely variable overall survival (OS) for patients. Although it has been found that focal adhesion genes are associated with clinical prognosis glioma patients, this marker rarely used clinically. Methods We systematically mRNA expression of related gliomas and explored their signature based on 938 samples from TCGA dataset CGGA dataset. Glioma were clustered using an unsupervised clustering method. Subsequently, prognosis-associated genes, gene (FARGS) was constructed least absolute shrinkage selection operator (LASSO) Cox regression. Additionally, multiple bioinformatics methods to examine value FARGS predicting patient outcomes, features, oncogenic pathways, immune microenvironment drug response. Furthermore, vitro vivo experiments conducted validate role RAP1B U87 cells. Results According LASSO regression analysis, a 9-FARG be strongly linked OS high-risk low-risk score pattern. tightly molecular biomarkers, including IDH wild-type, unmethylated MGMTp, non-codeletion 1p19q. group exhibited enrichment biological pathways. Interestingly, results presented strong association therapeutic response immunosuppressive infiltrations M2-type macrophages, MDSCs Tregs, elevated immunosuppressors’ expression. Lastly, cells also functionally confirmed. Conclusions In conclusion, we reported novel promising prediction as well confirmation RAP1B's role.

Language: Английский

A novel chemokine‐based signature for prediction of prognosis and therapeutic response in glioma DOI Creative Commons
Wenhua Fan, Di Wang, Guanzhang Li

et al.

CNS Neuroscience & Therapeutics, Journal Year: 2022, Volume and Issue: 28(12), P. 2090 - 2103

Published: Aug. 19, 2022

Abstract Aims Gliomas are the primary malignant brain tumor and characterized as striking cellular heterogeneity intricate microenvironment (TME), where chemokines regulate immune cell trafficking by shaping local networks. This study aimed to construct a chemokine‐based gene signature evaluate prognosis therapeutic response in glioma. Methods In this study, 1024 patients (699 from TCGA 325 CGGA database) with clinicopathological information mRNA sequencing data were enrolled. A chemokine was constructed combining LASSO SVM‐RFE algorithm. GO, KEGG, GSVA analyses performed for function annotations of signature. Candidate mRNAs subsequently verified through qRT‐PCR an independent cohort including 28 glioma samples. Then, immunohistochemical staining (IHC), we detected expression immunosuppressive markers explore role immunotherapy Lastly, Genomics Drug Sensitivity Cancer (GDSC) leveraged predict potential drug related Results significantly associated poorer survival, especially glioblastoma, IDH wildtype. It also played prognostic factor both datasets. Moreover, biological predictive indicated positively immune‐relevant pathways, protein expressions (PD‐L1, IBA1, TMEM119, CD68, CSF1R, TGFB1) enriched high‐risk group. glioblastoma cohort, confirmed showed good predictor patients' response. predicted twelve agents higher riskscore. Conclusion all, our results highlighted 4‐chemokine predicting reflected landscape threw light on integrating tailored risk stratification precision therapy glioblastoma.

Language: Английский

Citations

24
Relationship between chemokine/chemokine receptor and glioma prognosis and outcomes: Systematic review and meta-analysis DOI
Shaobo Yang, Minjie Luo,

Shun Yang

et al.

International Immunopharmacology, Journal Year: 2024, Volume and Issue: 133, P. 112047 - 112047

Published: April 16, 2024

Language: Английский

Citations

4
Decoding the heterogeneous subpopulations of glioblastoma for prognostic stratification and uncovering the promalignant role of PSMC2 DOI Creative Commons
Nana Zhou,

Jingsong Yan,

Mai Xiong

et al.

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: Feb. 17, 2025

Language: Английский

Citations

0
m6A regulator-based molecular classification and hub genes associated with immune infiltration characteristics and clinical outcomes in diffuse gliomas DOI Creative Commons

Jie Lu,

Siyu Chen, Wanming Hu

et al.

BMC Medical Genomics, Journal Year: 2025, Volume and Issue: 18(1)

Published: Feb. 24, 2025

m6A methylation modification is a new regulatory mechanism involved in tumorigenesis and tumor-immunity interaction. However, its impact on glioma immune microenvironment clinical outcomes remains unclear. Comprehensive expression profiles of 18 regulators were used to identify molecular subtypes exhibiting distinct patterns 1673 samples sourced from public datasets. A multi-genes signature was constructed for predicting response immunotherapy patients. Immunohistochemistry cellular experiments performed validation. Two gliomas identified. The m6A-low-risk subtype characterized by paucity infiltrates; While the m6A-high-risk had higher abundances multiple cells including lymphocyte macrophage as well increased PD-L1, corresponding an immunosuppressive phenotype. poorer survival than both glioblastoma lower grade cohorts. Eight m6A-related hub genes high prognostic significances identified selected developing scoring termed m6Ascore. Elevated m6Ascore indicated worse patients under standard care, but showed enhanced immunotherapy. Moreover, we demonstrated that overexpression FTO, demethylase, inhibited expressions (PTX3, SPAG4), impaired cell viability reduced chemotaxis. This work develops immune- clinical-relevant subtyping model, which enhances our understanding role regulating infiltration helps who are more likely benefit

Language: Английский

Citations

0
Developing and validating a prognostic disulfidptosis-related signature for glioblastoma: predicting radioresistance and synergestic effect with immunotherapy DOI Creative Commons
Chen Chen,

Peixin Tan,

Wenqing Feng

et al.

Journal of Cancer Research and Clinical Oncology, Journal Year: 2025, Volume and Issue: 151(3)

Published: March 18, 2025

Programmed cell death (PCD) modulated radioresistance is one of the predominant causes treatment failure in glioblastoma (GBM). Disulfidptosis, a newly discovered form PCD, plays crucial role GBM progression. However, association among disulfidptosis, radiosensitivity and radiotherapy (RT) remain unclear. We systematically analyzed disulfidptosis-related genes 1075 patients constructed gene signature (DRS). Correlations DRS, patient prognosis immune microenvironment were fully explored. The effects DRS EFEMP2 on efficacy investigated via single sequencing analysis validated vitro vivo experiments. was identified as robust independent prognostic biomarker for by multivariate Cox regression analysis, receiver operating characteristic (ROC) curve decision (DCA) multiple cohorts. High characterized radioresistance, proven to be key involved this process CCK-8 assay clonogenic survival assay. In high-DRS patients, cancer-immunity cycle attenuated because antitumor cytotoxicity CD8+ T cells inhibited checkpoints. Preclinically, overexpression induced enhancing programmed ligand-1 (PD-L1) blockade GL261-bearing mice. combination irradiation anti-PD-L1 therapy had synergistic effect murine models which overexpressed. Our study bioinformatically experimentally reveals molecular landscape disulfidptosis GBM, develops predictive predicting well provides that combines with immunotherapy radioresistant high or expression.

Language: Английский

Citations

0
The war between the immune system and the tumor - using immune biomarkers as tracers DOI Creative Commons
Kai Yang,

Rongrong Lu,

Jie Mei

et al.

Biomarker Research, Journal Year: 2024, Volume and Issue: 12(1)

Published: May 30, 2024

Abstract Nowadays, immunotherapy is one of the most promising anti-tumor therapeutic strategy. Specifically, immune-related targets can be used to predict efficacy and side effects monitor tumor immune response. In past few decades, increasing numbers novel biomarkers have been found participate in certain links immunity contribute formation immunosuppression entered clinical trials. Here, we systematically reviewed oncogenesis progression cancer view immunity, particularly terms antigen expression (related immunogenicity) innate complement cancer-immune cycle. From perspective integrated management chronic cancer, also appraised emerging factors affecting (including metabolic, microbial, exercise-related markers). We finally summarized studies applications based on biomarkers. Overall, promoting development more precise individualized by predicting, monitoring, regulating Therefore, targeting may lead innovative applications.

Language: Английский

Citations

3
Hypoxia‐related THBD+ macrophages as a prognostic factor in glioma: Construction of a powerful risk model DOI Creative Commons
Weichun Tang,

Juntao Du,

Lin Li

et al.

Journal of Cellular and Molecular Medicine, Journal Year: 2024, Volume and Issue: 28(10)

Published: May 1, 2024

Glioma is a prevalent malignant tumour characterized by hypoxia as pivotal factor in its progression. This study aims to investigate the impact of most severely hypoxic cell subpopulation glioma. Our findings reveal that THBD

Language: Английский

Citations

2
Histone acetylation risk model predicts prognosis and guides therapy selection in glioblastoma: implications for chemotherapy and anti-CTLA-4 immunotherapy DOI Creative Commons
Xingyi Jin,

Zhigang Qin,

Hang Zhao

et al.

BMC Immunology, Journal Year: 2024, Volume and Issue: 25(1)

Published: July 27, 2024

Abstract Background Glioblastoma is characterized by high aggressiveness, frequent recurrence, and poor prognosis. Histone acetylation-associated genes have been implicated in its occurrence development, yet their predictive ability glioblastoma prognosis remains unclear. Results This study constructs a histone acetylation risk model using Cox LASSO regression analyses to evaluate We assessed the model’s prognostic with univariate multivariate analyses. Additionally, immune infiltration was evaluated ESTIMATE TIMER algorithms, SubMAP algorithm utilized predict responses CTLA4 inhibitor. Multiple drug databases were applied assess sensitivity high- low-risk groups. Our results indicate that independent reliable predicting Conclusions Low-risk patients showed higher activity longer overall survival, suggesting anti-CTLA4 immunotherapy suitability, while high-risk might benefit more from chemotherapy. could guide personalized therapy selection for patients.

Language: Английский

Citations

2
Comprehensive analysis of basement membrane and immune checkpoint related lncRNA and its prognostic value in hepatocellular carcinoma via machine learning DOI Creative Commons
Ze Jin, Yajun Meng, Mengmeng Wang

et al.

Heliyon, Journal Year: 2023, Volume and Issue: 9(10), P. e20462 - e20462

Published: Sept. 27, 2023

BackgroundHepatocellular carcinoma (HCC), which is characterized by its high malignancy, generally exhibits poor response to immunotherapy. As part of the tumor microenvironment, basement membranes (BMs) are involved in development and immune activities. Presently, there no integrated analysis linking membrane with checkpoints, especially from perspective lncRNA.MethodsBased on transcriptome data The Cancer Genome Atlas, BMs-related checkpoint-related lncRNAs were identified. By applying univariable Cox regression Machine learning (LASSO SVM-RFE algorithm), a 10-lncRNA prognosis signature was constructed. prognostic significance this assessed survival analysis. GSEA, ssGSEA, drug sensitivity conducted investigate potential functional pathways, status, clinical implications guiding individual treatments HCC. Finally, promoting migration effect LINC01224 validated via vitro experiments.ResultsThe multiple regression, receiver operating characteristic curves, stratified subgroups exhibited robust ability lncRNA signature. Results GSEA revealed significant differences pathways drugs between two risk groups. In addition, level HCC patients distinctly correlated cell infiltration status. More importantly, independently associated OS (P < 0.05), suppressing expression inhibited cells.ConclusionThis study developed reliable for based BM checkpoint related lncRNA, revealing that might be biomarker progression

Language: Английский

Citations

4
Cuproptosis in glioblastoma: unveiling a novel prognostic model and therapeutic potential DOI Creative Commons

Zhigang Qin,

Bin Yang, Xingyi Jin

et al.

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: March 28, 2024

Glioblastoma, a notably aggressive brain tumor, is characterized by brief survival period and resistance to conventional therapeutic approaches. With the recent identification of “Cuproptosis,” copper-dependent apoptosis mechanism, this study aimed explore its role in glioblastoma prognosis potential implications. A comprehensive methodology was employed, starting with analysis 65 cuproptosis-related genes. These genes were subjected differential expression analyses between tissues normal counterparts. novel metric, “CP-score,” devised quantify cuproptosis response patients. Building on this, prognostic model, CP-model, developed using Cox regression techniques, designed operate both bulk single-cell data. The revealed 31 distinct patterns glioblastoma. CP-score markedly elevated patients, suggesting an intensified response. CP-model adeptly stratified patients into risk categories, unveiling intricate associations prognosis, immune pathways, tumor’s immunological environment. Further indicated that high-risk as per exhibited heightened certain checkpoints, targets. Additionally, model hinted at possibility personalized strategies, drugs showing increased efficacy offers promising tool for strategy development, emphasizing Cuproptosis cancer treatment.

Language: Английский

Citations

1